PCN73 Cost-Effectiveness of Pembrolizumab Versus Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma (ESCC) As the Second-LINE Treatment Among the Chinese Population
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.165
https://www.valueinhealthjournal.com/article/S1098-3015(21)00382-X/fulltext
Title :
PCN73 Cost-Effectiveness of Pembrolizumab Versus Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma (ESCC) As the Second-LINE Treatment Among the Chinese Population
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00382-X&doi=10.1016/j.jval.2021.04.165
First page :
Section Title :
Open access? :
No
Section Order :
10743